Cargando…

Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis

BACKGROUND: Surgery and stereotactic body radiotherapy (SBRT) are both suitable treatment options for early stage Non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer. This study compared the outcomes of sublobar resection (SLR) and SBRT in patients with stage T1-2N0M0...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Baiqiang, Zhu, Xuan, Jin, Jianan, Chen, Yuanyuan, Ying, Hangjie, Chen, Yamei, Lu, Fangxiao, Shen, Wei, Wang, Jin, Chen, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656409/
https://www.ncbi.nlm.nih.gov/pubmed/33209426
http://dx.doi.org/10.21037/jtd-20-2367
_version_ 1783608377272696832
author Dong, Baiqiang
Zhu, Xuan
Jin, Jianan
Chen, Yuanyuan
Ying, Hangjie
Chen, Yamei
Lu, Fangxiao
Shen, Wei
Wang, Jin
Chen, Ming
author_facet Dong, Baiqiang
Zhu, Xuan
Jin, Jianan
Chen, Yuanyuan
Ying, Hangjie
Chen, Yamei
Lu, Fangxiao
Shen, Wei
Wang, Jin
Chen, Ming
author_sort Dong, Baiqiang
collection PubMed
description BACKGROUND: Surgery and stereotactic body radiotherapy (SBRT) are both suitable treatment options for early stage Non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer. This study compared the outcomes of sublobar resection (SLR) and SBRT in patients with stage T1-2N0M0 NSCLC with tumor size ≤5 cm. METHODS: Patients with T1-2N0M0 lung cancer who underwent SLR or SBRT between January, 2012 and December, 2016 were included in this retrospective study. The survival outcomes and toxicity of the SLR and SBRT cohorts were compared using Kaplan-Meier survival plots. In a second exploratory analysis, propensity score matching (PSM) was applied to reduce selection bias between the two groups of patients. RESULTS: A total of 121 SLR and 109 SBRT cases were included. The average follow-up was 49.4 months. Prior to PSM, the 5-year overall survival (OS) and cancer-specific survival (CSS) rates in the SLR group (82.8% and 89.0%, respectively) were superior to those in the SBRT group (67.0% and 75.3%; P=0.001 and P=0.013, respectively). There were no statistically significant differences in the five-year locoregional control and disease-free survival (DFS) rates between the groups. PSM identified 40 patients from each treatment group who shared similar characteristics. At 5 years, the OS rates in the SLR and SBRT groups were comparable (79.9% vs. 66.5%, respectively; P=0.154). After PSM, the rates of CSS, locoregional control, and DFS were also similar between the groups (P=0.458, 0.369, and 0.698, respectively). In the SBRT group, one patient developed grade 3 radioactive pneumonitis. No grade >3 toxicities or treatment-related deaths occurred in either group. CONCLUSIONS: SBRT may be an alternative option to SLR for patients who cannot tolerate lobectomy because of medical comorbidities and has a similar level of effectiveness.
format Online
Article
Text
id pubmed-7656409
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-76564092020-11-17 Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis Dong, Baiqiang Zhu, Xuan Jin, Jianan Chen, Yuanyuan Ying, Hangjie Chen, Yamei Lu, Fangxiao Shen, Wei Wang, Jin Chen, Ming J Thorac Dis Original Article BACKGROUND: Surgery and stereotactic body radiotherapy (SBRT) are both suitable treatment options for early stage Non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer. This study compared the outcomes of sublobar resection (SLR) and SBRT in patients with stage T1-2N0M0 NSCLC with tumor size ≤5 cm. METHODS: Patients with T1-2N0M0 lung cancer who underwent SLR or SBRT between January, 2012 and December, 2016 were included in this retrospective study. The survival outcomes and toxicity of the SLR and SBRT cohorts were compared using Kaplan-Meier survival plots. In a second exploratory analysis, propensity score matching (PSM) was applied to reduce selection bias between the two groups of patients. RESULTS: A total of 121 SLR and 109 SBRT cases were included. The average follow-up was 49.4 months. Prior to PSM, the 5-year overall survival (OS) and cancer-specific survival (CSS) rates in the SLR group (82.8% and 89.0%, respectively) were superior to those in the SBRT group (67.0% and 75.3%; P=0.001 and P=0.013, respectively). There were no statistically significant differences in the five-year locoregional control and disease-free survival (DFS) rates between the groups. PSM identified 40 patients from each treatment group who shared similar characteristics. At 5 years, the OS rates in the SLR and SBRT groups were comparable (79.9% vs. 66.5%, respectively; P=0.154). After PSM, the rates of CSS, locoregional control, and DFS were also similar between the groups (P=0.458, 0.369, and 0.698, respectively). In the SBRT group, one patient developed grade 3 radioactive pneumonitis. No grade >3 toxicities or treatment-related deaths occurred in either group. CONCLUSIONS: SBRT may be an alternative option to SLR for patients who cannot tolerate lobectomy because of medical comorbidities and has a similar level of effectiveness. AME Publishing Company 2020-10 /pmc/articles/PMC7656409/ /pubmed/33209426 http://dx.doi.org/10.21037/jtd-20-2367 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Dong, Baiqiang
Zhu, Xuan
Jin, Jianan
Chen, Yuanyuan
Ying, Hangjie
Chen, Yamei
Lu, Fangxiao
Shen, Wei
Wang, Jin
Chen, Ming
Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis
title Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis
title_full Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis
title_fullStr Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis
title_full_unstemmed Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis
title_short Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis
title_sort comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage t1-2n0m0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656409/
https://www.ncbi.nlm.nih.gov/pubmed/33209426
http://dx.doi.org/10.21037/jtd-20-2367
work_keys_str_mv AT dongbaiqiang comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT zhuxuan comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT jinjianan comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT chenyuanyuan comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT yinghangjie comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT chenyamei comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT lufangxiao comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT shenwei comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT wangjin comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis
AT chenming comparisonoftheoutcomesofsublobarresectionandstereotacticbodyradiotherapyforstaget12n0m0nonsmallcelllungcancerwithtumorsize5cmapropensityscorematchinganalysis